Bioventus (BVS) Divestments (2022 - 2023)

Bioventus' (BVS) quarterly Divestments came in at -$11.5 million in Q2 2023, up 89.03% on a QoQ basis from -$104.8 million in Q4 2022.

Bioventus (BVS) Divestments (2022 - 2023) Analysis & Trends

Bioventus (BVS) has 2 years of Divestments data on file, last reported at -$11.5 million in Q2 2023.

Quarterly Divestments changed N/A year-over-year to -$11.5 million in Q2 2023, while the trailing twelve-month figure through Dec 2023 was -$11.5 million (up 89.03% YoY) and the FY2023 annual result came in at -$11.5 million, up 89.03% from the prior year.
Divestments grew to -$11.5 million in Q2 2023, from -$104.8 million in the prior quarter.
In the past five years, Divestments ranged from a high of -$11.5 million in Q2 2023 to a low of -$104.8 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Divestments (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	-
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	-
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	-
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	-
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	-
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	-
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	-
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	153.43 Mn
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	-
10	Bioventus	972.56 Mn	943.11 Mn	105.67 Mn	-

Download Data